AVTX

Avalo Therapeutics' stock has experienced significant events in the past six months. The share price was $13.78 as of May 4, 2026, a 174.50% increase from May 5, 2025. Positive Phase 2 trial results for abdakibart in hidradenitis suppurativa have driven valuation. A $375 million public offering was announced in May 2026 to advance abdakibart's clinical development. Several analyst firms have issued positive reports and increased their price targets for AVTX. Avalo Therapeutics insiders have sold approximately $2,501,346.00 in company stock in the past 90 days. The company reported quarterly earnings data, with ($0.37) EPS for the quarter, topping analysts' estimates of ($1.54).